Nouscom Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 26
Employees
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $14M
Latest Deal Amount
  • Investors
  • 4

Nouscom General Information

Description

Developer of next-generation immunotherapies created to combat cancer by activating cancer-specific T cells. The company's immunotherapies harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neo-antigens with other immunomodulators, enabling patients to get clinical treatment

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • Bäumleingasse 18
  • 4051 Basel
  • Switzerland
+41 061 000 00 00

Nouscom Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Nouscom Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 04-Feb-2020 $14M 000.00 0000 Completed Generating Revenue
2. Early Stage VC (Series B) 06-Nov-2017 000.00 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 17-May-2016 $13.6M $13.6M Completed Startup
To view Nouscom’s complete valuation and funding history, request access »

Nouscom Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000 0000.00 0000.00 00 0000.00 00.00
Series B 00,000 0000.00 0000.00 00 0000.00 00.000
Series A 18,330 $181.52 $181.52 1x $181.52 4.71%
To view Nouscom’s complete cap table history, request access »

Nouscom Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of next-generation immunotherapies created to combat cancer by activating cancer-specific T cells. The company
Biotechnology
Basel, Switzerland
26 As of 2020
000.00
000 0000-00-00
0000000000 0 000.00

00000 00

ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor i
0000 000000000
Geneva, Switzerland
00 As of 0000
00000
0000000000 0 00000

000000 0

ore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip
0000000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nouscom Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Light Chain Bioscience Venture Capital-Backed Geneva, Switzerland 00 00000 0000000000 0 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
000000000 00000000 Venture Capital-Backed Schlieren, Switzerland 0 000.00 00000000000 000.00
00000 Private Equity-Backed San Diego, CA 00 00000 0000000 0000 00000
000000 Private Equity-Backed Cambridge, United Kingdom 000 0000 0000000 0000 0000
You’re viewing 5 of 9 competitors. Get the full list »

Nouscom Executive Team (12)

Name Title Board Seat Contact Info
Marina Udier Ph.D Chief Executive Officer & Board Member
Stefano Colloca MD Co-Founder, Chief Technical Officer & Advisor
Elisa Scarselli MD Co-Founder & Chief Scientific Officer
Richard Davis Ph.D Chief Business Officer
Antonella Folgori Ph.D Co-Founder, Senior Director, Immunology & Advisor
You’re viewing 5 of 12 executive team members. Get the full list »

Nouscom Board Members (11)

Name Representing Role Since
Genghis Lloyd-Harris Ph.D Abingworth Management Board Member 000 0000
Gianni Gromo Ph.D Versant Venture Board Observer 000 0000
Göran Ando MD Self Chairman & Board Member 000 0000
Jean-Paul Prieels Ph.D Self Independant Board Member 000 0000
Joachim Rothe Ph.D Life Sciences Partners Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Nouscom Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nouscom Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
5AM Ventures Venture Capital Minority 000 0000 000000 0
Abingworth Management Venture Capital Minority 000 0000 000000 0
Life Sciences Partners Venture Capital Minority 000 0000 000000 0
Versant Venture Venture Capital Minority 000 0000 000000 0
To view Nouscom’s complete investors history, request access »